This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Patient Compliance to a New Enteric-Coated Weekly Formulation of Fluoxetine During Continuation Treatment of Major Depressive Disorder

Ami Claxton, Erik de Klerk, Mark Parry, James M. Robinson, and Mark E. Schmidt

Published: December 31, 2000

Article Abstract

Background: A new formulation of enteric-coatedfluoxetine given once weekly could be a useful option for thelong-term treatment of depression, but compliance to once-weeklyfluoxetine treatment has not been assessed.

Method: Patients were adults from the UnitedKingdom who had responded to fluoxetine treatment for a currentepisode of depression (DSM-IV criteria). In the baselineassessment phase, all patients (N = 117) were continued on 20 mgof open-label fluoxetine once daily for 4 weeks. In the follow-upphase, patients (N = 109) were randomly assigned to once-weeklyor once-daily fluoxetine for 3 months. Patient compliance wasmonitored by electronic devices during both phases of the study.

Results: Compliance to once-weekly fluoxetinetreatment was higher than compliance to once-daily fluoxetine(85.9% vs. 79.4%, respectively).

Conclusion: Once-weekly fluoxetine treatmentallows for new flexibility for both the clinician and thepatient, and this study alleviates the concern that patients willforget weekly doses.

Volume: 61

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...